Whole Genome Sequencing
Genome-wide sequencing across all chromosomes detects mutations, copy-number and structural changes, with broad detection of circulating tumor DNA.
Offered within the Human Longevity care experience
Caris Detect™Multi-Cancer Early Detection
Multi-cancer early detection blood test
The Future of Detecting Cancer Earlier.
Caris Detect looks across DNA and RNA signals to identify cancer-associated biology from a routine blood draw—before symptoms may appear.
Caris Detect$3,500
Early biology.Early insight.Early action.KNOW EARLY
The screening need
Most cancers are never routinely screened for.
Only a small number of cancers have guideline-recommended screening. Existing screening is organ-specific, and many cancers become detectable only after they are anatomically visible.
Broadening early-stage screening represents a significant unmet need. Caris Detect is designed to complement—not replace—guideline-recommended screening.
31%of cancers diagnosed each year fall within current USPSTF screening guidelines*
69%of annual cancer deaths occur in cancers without routine screening options
*USPSTF Grade A or B recommendations for routine screening. Sources: NORC at the University of Chicago, “New Research Highlights Just One In Seven Diagnosed Cancers Found By A Recommended Screening Test,” Dec. 14, 2022; U.S. Preventive Services Task Force recommendation topics; CDC cancer screening tests.
A multi-omic view
Early-stage cancer is not a single signal.
Caris Detect integrates DNA, RNA and AI-driven interpretation to provide a more complete view of cancer biology.
Whole Transcriptome Sequencing
Measures total gene expression, detects fusions and active pathways, and captures real-time tumor biology.
Proprietary Caris GPSai®
Matches molecular profiles to cancer-specific signatures and provides a suspected tissue of origin to help guide follow-up evaluation.
Built on years of experience
The science did not begin with Caris Detect.
1M+cancer cases
50B+molecular markers
18years in precision oncology
240×sequencing depth
55+cancers detected
Caris Detect is built on decades of precision oncology experience, combining deep whole-genome sequencing with insights from more than 1 million cancer cases and 50 billion molecular markers.
Key evidence
Performance grounded in a broad biological view.
99.2%Specificity in the asymptomatic screening population1
60.3%Sensitivity in detecting stage I and stage II cancers1
Designed to help guide what comes next
Caris Detect predicts a suspected tissue of origin to help guide follow-up evaluation. The source reports early-stage detection across lung, pancreas, prostate, breast, colorectal, uterine and additional cancer types.
Important qualification
Performance data were generated using 4 of the 9 AI pillars described in the source. Additional pillars may further strengthen overall performance. Total data set sample size by tumor type: breast 297; prostate 58; lung 30; uterine 32; bowel 55; head and neck 16; pancreatic 10; other 30.
Designed for preventive care
Test. Know. Act.
A simple process built to turn comprehensive molecular analysis into clinically supported next steps.
- 01
Test
A standard blood draw is analyzed using WGS, WTS and comprehensive molecular analysis in a CLIA-certified, CAP-accredited laboratory.
- 02
Know
Results provide a clear category and, when appropriate, suspected tissue-of-origin guidance with dedicated clinical care support.
- 03
Act
Physicians and patients use the report to consider targeted evaluation, patient navigation and ongoing prevention planning.
Patient fit
For adults who want to know early.
Caris Detect is intended for adults 21 years and older seeking a more comprehensive approach to finding cancer early.
01
Age-associated risk
Adults 50+ may especially value broader early-detection insight.
02
Family history
For people with family history or genetic predisposition.
03
Unscreened cancers
For those concerned about cancers without routine screening.
04
Exposure and lifestyle
For people considering known exposure or lifestyle risks.
05
Prevention focused
For individuals seeking a more comprehensive preventive approach.
Results designed for clinical action
A clear result—and a path forward.
A screening result is not a diagnosis. Each category is designed to support an informed conversation with a physician.
No Cancer Signal Detected
No cancer-associated molecular signals were identified in the blood sample at the time of testing.
What this means
Continue all routine cancer screening recommended for your age, sex, personal medical history and family history.
Atypical Signal Detected
Findings may represent atypical biological activity requiring additional clinical evaluation.
What this means
The source describes physician follow-up and complimentary repeat testing in approximately three months.
Cancer Signal Detected
Cancer-associated molecular signals warrant timely diagnostic evaluation.
What this means
Suspected tissue-of-origin information may guide additional targeted screening or diagnostic evaluation.
The HLI integrated approach
Cancer risk is not one-dimensional.
A fuller cancer-risk picture can require more than one kind of signal. HLI brings together inherited risk, anatomical imaging and blood-based molecular information to support a more individualized clinical strategy.
Inherited predisposition
Whole genome sequencing
HLI's whole genome sequencing can surface inherited predisposition and help inform a cancer-risk assessment tailored to personal and family context.
Explore genomicsAnatomical insight
Whole Body MRI
Whole Body MRI can look across the body for anatomically visible disease without ionizing radiation.
Explore Whole Body MRIMolecular insight
Caris Detect
Caris Detect adds blood-based DNA and RNA signals that may identify cancer-associated biology and help guide follow-up evaluation.
Screening does not detect every cancer. The appropriate combination and timing of tests requires individualized clinical guidance and should complement guideline-recommended screening.
Clinical partnership
Knowing is only useful when you know what comes next.
- Dedicated clinical care consultation for patients and physicians
- Personalized patient navigation through the follow-up journey
- Physician-focused reporting with suspected tissue-of-origin guidance when appropriate
- Ongoing partnership within a prevention-focused care experience
Caris Detect™Multi-Cancer Early Detection
Bring earlier insight into your preventive care conversation.
Human Longevity can help you understand how Caris Detect may fit alongside—not in place of—recommended screenings and clinical care.
Caris Detect$3,500
Speak with an HLI specialist Sources & important information
1 Abraham J, Domenyuk V, Perdigones N, et al. “Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors.” Scientific Reports. 2025;15. doi:10.1038/s41598-025-08986-0.
Caris Detect is intended to complement, not replace, recommended cancer screening tests and other medical evaluations. A “No Cancer Signal Detected” result does not completely rule out cancer. Not all cancers can be detected through blood-based testing. An “Atypical Signal Detected” result does not confirm cancer, and a “Cancer Signal Detected” result is not itself a diagnosis. Clinical follow-up may be appropriate based on medical history, risk factors, symptoms and other diagnostic findings.
This Human Longevity page presents information supplied in the August 2026 Caris Detect source material. It describes how the test may be integrated into an HLI preventive-care conversation and does not state current availability, regulatory status, coverage or individual eligibility.